Personalized Medicine Portfolio
This collection features innovative companies revolutionizing healthcare by developing treatments tailored to individual genetic profiles. Carefully selected by our analysts, these stocks represent the cutting edge of precision medicine, where customized therapies aim to deliver more effective patient outcomes.
Top Picks from This Group
Here are a few of the assets in this group. Create an account to unlock the full list.
About This Group of Stocks
Our Expert Thinking
The healthcare industry is shifting from one-size-fits-all treatments to therapies designed for specific genetic profiles. Companies in this collection are pioneering technologies that target diseases at their molecular source, potentially offering more effective treatments with fewer side effects.
What You Need to Know
This portfolio includes companies at various stages of innovation—from diagnostic tools to therapeutic development. Consider this an aggressive growth component for your investments, as many firms are still developing commercial pathways for their technologies.
Why These Stocks
These companies were selected for their leadership in genomic sequencing, biomarker discovery, and targeted therapies like CRISPR gene editing. Recent regulatory approvals for gene-specific treatments and AI advancements in drug discovery provide significant growth catalysts.
12 Month Growth Potential
Use the growth calculator to see how much investing in these assets could return over one year.
If you invested across these assets:
in 12 months it could be worth:
+248.54%
Group Performance Snapshot
Average 12 Month Profit
On average, analysts expect assets in this group to grow 248.54% over the next year.
Stocks Rated Buy by Analysts
14 of 16 assets in this group are rated Buy by professional analysts.
Group Growth vs Bank interest
This group averaged a 5.2% return last month, beating the typical 4% bank rate.
Why You'll Want to Watch These Stocks
The DNA of Future Medicine
Personalized medicine is rewriting healthcare's rulebook. These companies are at the forefront of a revolution that could make traditional treatments obsolete while creating entirely new markets.
Breakthrough Momentum
Recent regulatory approvals for gene therapies are accelerating the path to market. As more personalized treatments gain validation, these pioneering companies could see rapid adoption and growth.
Beyond One-Size-Fits-All
Imagine treatments designed specifically for your genetic code. These companies are making this a reality, potentially capturing massive value as healthcare shifts toward precision therapies with better outcomes.
Why Invest with Nemo Money?
Zero Commission
Trade stocks, ETFs, and more with zero commission. Keep more of your returns.
Trusted & Regulated
Part of Exinity Group 2015, serving over a million customers globally.
6% Interest on Cash
Earn 6% AER on uninvested cash with daily interest payments.
Discover More Opportunities
Orphan Drug Moats: Leaders In Rare Disease
The FDA's rejection of PTC Therapeutics' drug for a rare genetic disorder has delayed a new treatment option and created a significant setback for the company. This regulatory decision strengthens the competitive position of companies with already-approved therapies for rare diseases, highlighting the value of a proven drug portfolio.
Nvidia's China Chip Pivot
Nvidia is developing a new, compliant AI chip for China, aiming to recapture market share lost to U.S. export controls. This strategic pivot creates a ripple effect, potentially benefiting the entire semiconductor supply chain that supports the production and deployment of this advanced hardware.
Navigating The Autonomous Driving Shakeout
A class-action lawsuit against Tesla regarding its Full Self-Driving claims puts the company's marketing and technology under intense scrutiny. This legal challenge could boost demand for competing autonomous driving technologies, creating opportunities for companies that supply advanced sensors and software.
Frequently Asked Questions
Everything you need to know about the product and billing.